Evidence map›Paper›PMID 26410102›Full record

Trial reportInternational journal of hematology2015

Favorable outcome in non-infant children with MLL-AF4-positive acute lymphoblastic leukemia: a report from the Tokyo Children's Cancer Study Group.

Daisuke Tomizawa, Motohiro Kato, Hiroyuki Takahashi, Junya Fujimura, Takeshi Inukai, Takashi Fukushima, Nobutaka Kiyokawa, Katsuyoshi Koh, Atsushi Manabe, Akira Ohara

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Daisuke TomizawaDivision of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. tomizawa-d@ncchd.go.jp.
Motohiro KatoDivision of Transplantation and Cell Therapy, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Hiroyuki TakahashiDepartment of Pediatrics, Toho University, Tokyo, Japan.
Junya FujimuraDepartment of Pediatrics and Adolescent Medicine, Juntendo University School of Medicine, Tokyo, Japan.
Takeshi InukaiDepartment of Pediatrics, Yamanashi University, Kofu, Japan.
Takashi FukushimaDepartment of Pediatrics, University of Tsukuba, Tsukuba, Japan.
Nobutaka KiyokawaDepartment of Pediatric Hematology and Oncology Research, National Center for Child Health and Development, Tokyo, Japan.
Katsuyoshi KohDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Atsushi ManabeDepartment of Pediatrics, St. Luke's International Hospital, Tokyo, Japan.
Akira OharaDepartment of Pediatrics, Toho University, Tokyo, Japan.
National Center For Child Health and Development · JPToho University · JPJuntendo University · JPSaitama Children's Medical Center · JPSt. Luke's International Hospital · JPUniversity of Tsukuba · JPUniversity of Yamanashi · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unlike acute lymphoblastic leukemia (ALL) in infants, MLL gene rearrangement (MLL-r) is rare in ALL children (≥1 year old). The outcome and optimal treatment options for MLL-r ALL remain controversial. Among the 1827 children enrolled in the Tokyo Children's Cancer Study Group ALL studies L95-14, L99-15, L99-1502, L04-16, and L07-1602 (1995-2009), 25 MLL-r ALL patients (1.3 %) were identified. Their median age and leukocyte count at diagnosis was 2 years old (range 1-15 years) and 27,690/μL (range 1800-1,113,000/μL), respectively. All but one patient achieved complete remission (CR) after induction therapy, and 19 underwent allogeneic hematopoietic stem cell transplantation (HSCT) in first CR according to the protocol. The 5-year event-free survival (EFS) and overall survival (OS) rate were 60.0 % [standard error (SE), 9.7 %] and 64.0 % (SE 9.6 %), respectively. Notably, 9/12 cases with MLL-AF4-positive ALL are alive in continuous CR with a 75.0 % (SE 12.5 %) EFS rate. The causes of treatment failure were as follows: one induction failure, five relapses, and five transplant-related deaths. With intensive chemotherapy and allogeneic HSCT, favorable outcome of children (≥1 year old) with MLL-AF4-positive ALL was observed. However, considering the risk of acute and late toxicities associated with HSCT, its indication should be restricted.

Indexed as

Hematopoietic Stem Cell TransplantationAdolescentAllograftsChildChild, PreschoolDisease-Free SurvivalFemaleHumansInfantJapanLeukocyte CountMaleMyeloid-Lymphoid Leukemia ProteinOncogene Proteins, FusionPrecursor Cell Lymphoblastic Leukemia-LymphomaSurvival RateMLL-AF4 fusion protein, humanMyeloid-Lymphoid Leukemia ProteinOncogene Proteins, FusionAcute lymphoblastic leukemiaChildrenHematopoietic stem cell transplantationMLL

Identifiers

PMID26410102
OpenAlexW1793098412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.